首页> 外文期刊>Dermatology Online Journal >The use of a sunscreen containing DNA-photolyase in the treatment of patients with field cancerization and multiple actinic keratoses: a case-series
【24h】

The use of a sunscreen containing DNA-photolyase in the treatment of patients with field cancerization and multiple actinic keratoses: a case-series

机译:含DNA-光解酶的防晒霜在治疗野癌和多发性光化性角化病患者中的应用:病例系列

获取原文
       

摘要

Cutaneous field cancerization (CFC) is associated witha high-risk of developing cutaneous squamous cellcarcinoma (cSCC). It manifests as actinic keratoses(AK) as one of the few macroscopic alterations in CFCpatients. A prospective, single-arm, case-series wasperformed to evaluate the utility of a novel sunscreencontaining DNA-photolyase for treatment of CFCin nine subjects (mean age 70.6 years, male: femaleratio 5:4). The cream was applied topically twicedaily on CFC/AK areas and patients were followedup for three months, with no other treatments. Theprimary outcome was the overall response rate (ORR),categorized as complete response (CR, completeresolution of AKs), partial response (PR, reduction inthe number of AKs), and no-response (NR, similar/increase in number of AKs). A 100% PR was observed.All subjects displayed at minimum, a 50% reductionin their lesion number and most patients experiencedalmost CR. Evaluation of AK numbers revealed anabsolute count reduction of 76.6% in the number oflesions, with the mean number of lesions reducedfrom 13.4 to 3.1 (p & 0.0001). No adverse events werereported. Patients with CFC may benefit from noveltopical applications containing DNA-photolyase,at minimum, as complementary therapy for themanagement of CFC disease. We propose a newconcept called “active photoprotection” because of itsdual mechanism involving therapy and protection.
机译:皮肤癌(CFC)与发展中的皮肤鳞状细胞癌(cSCC)的高风险有关。它表现为光化性角化病(AK),是CFC患者中为数不多的宏观变化之一。进行了前瞻性单臂病例系列研究,以评估新型防晒霜含DNA-光解酶在9位受试者(平均年龄70.6岁,男性:女性比例5:4)中治疗CFC的效用。该乳霜每天两次在CFC / AK区域局部使用,对患者进行了三个月的随访,没有其他治疗方法。主要结局是总体缓解率(ORR),分为完全缓解(CR,完全缓解AK),部分缓解(PR,减少AK数量)和无应答(NR,相似/增加的AK数量) 。观察到PR为100%,所有受试者均表现出最低程度,病灶数减少50%,大多数患者的CR最高。 AK数的评估表明,绝对计数减少了77.6%的病灶,平均病灶数从13.4降低到3.1(p <0.0001)。没有不良反应的报道。患有CFC的患者可至少接受含有DNA-光解酶的新型局部应用,作为治疗CFC疾病的补充疗法。由于其涉及治疗和保护的双重机制,我们提出了一个称为“主动光保护”的新概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号